- Home
- CVKD vs ANEB Comparison
CVKD vs ANEB Comparison
Compare CVKD & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- ANEB
- Stock Information
- Founded
- CVKD 2022
- ANEB 2020
- Country
- CVKD United States
- ANEB United States
- Employees
- CVKD N/A
- ANEB N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- ANEB Biotechnology: Pharmaceutical Preparations
- Sector
- CVKD Health Care
- ANEB Health Care
- Exchange
- CVKD Nasdaq
- ANEB Nasdaq
- Market Cap
- CVKD 27.0M
- ANEB 111.8M
- IPO Year
- CVKD 2023
- ANEB 2021
- Fundamental
- Price
- CVKD $13.67
- ANEB $2.64
- Analyst Decision
- CVKD Strong Buy
- ANEB Buy
- Analyst Count
- CVKD 1
- ANEB 2
- Target Price
- CVKD $32.00
- ANEB $8.00
- AVG Volume (30 Days)
- CVKD 25.7K
- ANEB 20.2K
- Earning Date
- CVKD 11-07-2025
- ANEB 11-14-2025
- Dividend Yield
- CVKD N/A
- ANEB N/A
- EPS Growth
- CVKD N/A
- ANEB N/A
- EPS
- CVKD N/A
- ANEB N/A
- Revenue
- CVKD N/A
- ANEB N/A
- Revenue This Year
- CVKD N/A
- ANEB N/A
- Revenue Next Year
- CVKD N/A
- ANEB N/A
- P/E Ratio
- CVKD N/A
- ANEB N/A
- Revenue Growth
- CVKD N/A
- ANEB N/A
- 52 Week Low
- CVKD $8.74
- ANEB $0.80
- 52 Week High
- CVKD $22.90
- ANEB $3.42
- Technical
- Relative Strength Index (RSI)
- CVKD 52.63
- ANEB 55.13
- Support Level
- CVKD $12.71
- ANEB $2.50
- Resistance Level
- CVKD $13.49
- ANEB $2.76
- Average True Range (ATR)
- CVKD 0.77
- ANEB 0.13
- MACD
- CVKD -0.07
- ANEB 0.00
- Stochastic Oscillator
- CVKD 69.42
- ANEB 61.82
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.